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Interleukin (IL)-21 is a c-dependent cytokine pro-
duced by activated T cells with important actions for T,
B, and NK cells. The IL-21 gene is adjacent to the IL-2
gene, and like IL-2, IL-21 is strongly induced at the tran-
scriptional level after T cell activation. Interestingly,
however, in contrast to the IL-2 gene, a calcium iono-
phore alone was sufficient to induce IL-21 gene expres-
sion in preactivated T cells. Two DNase I hypersensitiv-
ity sites were found in the IL-21 gene, corresponding to
nucleotide sequences that are conserved in humans and
mice. One site is located at the IL-21 promoter region
and conferred T cell receptor-mediated IL-21 gene tran-
scription. TCR-induced IL-21 gene expressionwas inhib-
ited by cyclosporin A and FK506. Correspondingly, the
IL-21 5-regulatory region contains three NFAT binding
sites, and induction of IL-21 promoter activity was im-
pairedwhen these sites weremutated or following treat-
ment with cyclosporin A. Thus, our studies reveal that in
contrast to IL-2, a calcium signal alone is sufficient to
mediate induction of the IL-21 in preactivated T lympho-
cytes and that this induction appears to result from
specific NFAT binding.
Interleukin (IL)1-21 is a type I cytokine whose receptor is
most closely related to the IL-2 receptor  chain and is ex-
pressed on T, B, and NK cells (1–3). Like IL-2, IL-4, IL-7, IL-9,
and IL-15, IL-21 utilizes the common cytokine receptor  chain
(c) (1, 4, 5). Analogous to other cytokines that utilize c, IL-21
activates Jak1 and Jak3 to initiate signal transduction, but
unlike other c-dependent cytokines, which predominantly ac-
tivate Stat5 proteins (IL-2, IL-7, IL-9, and IL-15) or Stat6
(IL-4), IL-21 preferentially activates Stat1 and Stat3 (2, 4).
IL-21 is produced by activated CD4 T cells and affects the
growth, survival, and functional activation of lymphocytes (3).
IL-21 acts in vitro as a co-mitogen for anti-CD3-induced thy-
mocyte and peripheral T cell proliferation (3), it augments NK
cell expansion and differentiation from human CD34 cells
when cultured with IL-15 and Flt-3 ligand (3), and it activates
NK-cytolytic activity (3, 6).
In addition to its effects on T cells, IL-21 can enhance the
proliferative response of human and murine B cells stimulated
in vitro with antibodies to CD40, but it inhibits B cell prolifer-
ation in response to anti-IgM IL-4 (3) and can augment B cell
death (7, 8). Within the B cell lineage, IL-21 critically regulates
immunoglobulin (Ig) production and cooperates with IL-4 for
the production of multiple antibody classes in vivo (9). IL-
21R/ mice have markedly diminished IgG1 but greatly ele-
vated IgE levels in response to antigen (9), and correspond-
ingly, IL-21 can inhibit antigen-induced IgE production (10).
Mice lacking expression of both IL-21R and IL-4 exhibit a
dysgammaglobulinemia with severely impaired IgG and IgE
responses (9). IL-21 differentially influences B cell fate depend-
ing on the signaling context. Although IL-21 induces the death
of resting B cells (7), it promotes differentiation of B cells
activated in a T cell-dependent manner into memory and
plasma cells, explaining how IL-21 can be proapoptotic for B
cells in vitro yet critical for antigen-specific immunoglobulin
production in vivo (8).
In T cells, IL-21 can cooperate with IL-15 or IL-7 to drive the
expansion of T cells, particularly of CD8 T cells (11). This
effect correlates with the ability of IL-21 to promote cytolytic
activity and anti-tumor effects (11). IL-21 has also been re-
ported to act on NK cells. One report indicated that it can
increase NK cell maturation, whereas another suggested it can
inhibit NK cell expansion (3, 6). To better understand the basis
for regulation of this critical cytokine, we now have studied the
regulatory elements controlling expression of this gene.
MATERIALS AND METHODS
Mice and Cell Culture—C57BL/6 mice were obtained from the Jack-
son Laboratory. NFATc2 knock-out mice were a gift from L.H. Glimcher
(Harvard School of Public Health, Boston, MA). Mice used in these
experiments were 8–10 weeks of age. All experiments were performed
under protocols approved by the National Institutes of Health Animal
Use and Care Committee and followed the NIH guidelines “Using
Animals in Intramural Research.” Single-cell suspensions from the
spleen were prepared and cultured at 1 106/ml in RPMI 1640 medium
containing 10% fetal bovine serum, 2 mM glutamine, 100 units/ml
penicillin G, and 100 g/ml streptomycin. CD4 T cells were isolated
from the spleens by positive selection with MACS purification (Miltenyi
Biotech). These isolated CD4 T cells were activated by incubating in
the presence of 2 g/ml of anti-CD3 and 2 g/ml of anti-CD28 mAbs
(Pharmingen) for 2 days and expanded in the presence of 100 units/ml
of IL-2 for another day.
5-RACE—5-RACE was performed using the GeneRacer kit (Invitro-
gen). Total cellular RNA isolated from activated CD4 T cells was
dephosphorylated using calf intestinal alkaline phosphatase, and the
5-“cap” of mRNA was removed using tobacco acid pyrophosphatase. An
RNA oligonucleotide was then ligated to the full-length, decapped
mRNAs, and reverse transcription was performed using oligo(dT) as a
primer. The resultant cDNAs were PCR-amplified using the GeneRacer
5-primer and a primer specific for the IL-21 gene (5-TTCAGCTGT-
TCAACAATGTC-3). The GeneRacer 5-nested primer and the same
IL-21 primer were then used in a second, nested PCR.
Quantitative Real Time PCR—CD4 splenocytes isolated from
C57BL/6 mice were activated with anti-CD3 and anti-CD28 for 2 days,
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and these activated cells were washed and then cultured in the pres-
ence of IL-2 for 1 day. Total RNA was isolated from these preactivated
CD4 T cells using TRIzol (Invitrogen). First-strand cDNAs were made
using the Omniscript RT Kit (Qiagen). Quantitative real time PCR was
performed on a 7900H sequence detection system (Applied Biosystems).
The sequences of the primers and TaqMan probes were as follows:
murine IL-21, 5-AAGATTCCTGAGGATCCGAGAAG-3, 5-GCATTC-
GTGAGCGTCTATAGTGTC-3, and 5-(6-FAM)-TTCCCGAGGACTGA-
GGAGACGCC-(TAMRA-6-FAM)-3; murine IL-2, 5-CCTGAGCAGGA-
TGGAGAATTACA-3, 5-TCCAGAACATGCCGCAGAG-3, and 5-(6-F-
AM)-CCCAAGCAGGCCACAGAATTGAAAG-(TAMRA-6-FAM)-3;
murine IL-4, 5-ACAGGAGAAGGGACGCCAT-3, 5-GAAGCCCTACAG-
ACGAGCTCA-3, 5-(6-FAM)-TCCTCACAGCAACGAAGAACACCACA-
(TAMRA-6-FAM)-3; murine 18 S rRNA, 5-CCTTTAACGAGGAT-
CCATTGGA-3, 5-ACGAGCTTTTTAACTGCAGCAA-3, and 5-(6-FAM)-
CGCGGTAATTCCAGCTCCAATAGCGTATATT-(TAMRA-6-FAM)-3.
DNase I Hypersensitivity Assay—DNase I hypersensitivity assays
were performed using isolated nuclei from preactivated T cells as pre-
viously described (12). The DNA was digested with NsiI (6538 and
7125) and analyzed on Southern blots (Nytran Plus, Schleicher &
Schuell) using random primer-labeled probes (from 6526 to 7130)
and Quickhyb solution (Stratagene).
Plasmid Constructs—To generate the wild type (WT) mouse IL-21
promoter luciferase reporter construct, we subcloned the Il21 gene
1605 to 75 region 5 to the luciferase gene between the BgiII and
MluI sites in the polylinker of the pGL3-Basic luciferase reporter vector
(Promega). Site-directed mutagenesis of the Il21 NFAT sites in this
plasmid was performed using the QuikChange kit (Stratagene). Three
mutagenic primers, 5-CCATGTGTCTCTTTTTAAGGTCTAAGATGCA-
GATG-3, 5-CGTACACCTAGCCAACTTAAAAGAAAAACGAGTTAC-
3, and 5-CACTATACAAAGATTTAAGGGCTGCAATGGGAGGG-3
were used to introduce the indicated underlined 3-bp changes into the
NFAT sites at203,121, and76, respectively. Fragments spanning
HS2 (1139 to 1683) were generated by PCR and cloned in both
orientations 5 and 3 to the SV40 promoter in pGL3-Promoter.
FIG. 1. Quantitative real time PCR analysis of IL-21 expression in murine T lymphocytes. Murine T lymphocytes were activated with
anti-CD3  anti-CD28 (CD3  CD28) mAbs for 2 days, washed, and then expanded for another day. Cells were then either not stimulated or
cultured in the presence of several different stimuli for 4 h, and IL-21 (A) and IL-2 (B) mRNA levels were analyzed by real time PCR. Where
indicated, inhibitors (actinomycin D, cycloheximide, CsA, FK506, and rapamycin) were added 30 min before treatment with anti-CD3, anti-CD28,
phorbol 12-myristate 13-acetate (PMA), or ionomycin. For each sample, the bar represents the mean ratio  S.E. of IL-21 (A) or IL-2 (B) mRNA
to that of 18 S ribosomal mRNA.
FIG. 2. Characterization of DNase I hypersensitive sites of
the mouse IL-21 gene. A, schematic showing locations of HS1 and
HS2 in the mouse Il21 gene. The thick bar represents the probe; the
five exons of the gene are shown. B, nuclei were isolated from preac-
tivated T lymphocytes cultured for 1 h in the absence or presence of
anti-CD3  anti-CD28 (CD3  CD28) and then digested with
DNase I as indicated. DNA was extracted, digested with NsiI, and
analyzed on 0.6% agarose gels. HSs were mapped by hybridizing
NsiI-digested DNA with the probe indicated in A.
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Transient Transfections and Luciferase Assays—Transient transfec-
tions of normal mouse T cells were performed by electroporation, as
described previously (13).
Electrophoretic Mobility Shift Assays (EMSAs)—CD4 splenocytes
isolated from C57BL/6 mice were activated with anti-CD3 and anti-
CD28 mAbs for 2 days, and these activated cells were washed and then
cultured in the presence of IL-2 for 1 day. Nuclear extracts were pre-
pared as described (14) from these untreated preactivated CD4 cells or
cells that had been treated with anti-CD3 mAb for 1 h at 37 °C. EMSAs
were performed as described previously (13) using 5% polyacrylamide
FIG. 3. Sequence of human and murine HS1 and HS2. Sequence comparison of the HS1 (A) and HS2 (B) regions of human and murine IL-21
genes. Boxed are potential binding sites for NFAT proteins in the HS1 region, and for AP1 and IRF1 proteins in the HS2 region. In A, the
transcription start site of the murine IL-21 gene is underlined and indicated by the arrow.
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gels (29:1 acrylamide:bisacrylamide) containing glycerol and 0.5 Tris
borate-EDTA buffer. For supershifting assays, nuclear extracts were
preincubated for 10 min with NFATc1 or NFATc2 mouse mAbs (Affinity
Bioreagents, Inc., Golden, CO). Oligonucleotide sequences from the
IL-21 promoter and IL-2 distal NFAT binding sites used as probes are
shown in Fig. 5A.
Chromatin Immunoprecipitation—Chromatin immunoprecipitation
assays were performed essentially as described (12, 13). CD4 spleno-
cytes isolated from C57BL/6 mice were activated with anti-CD3 and
anti-CD28 mAbs for 2 days, and these activated cells were washed and
then cultured in the presence of IL-2 for 1 day. These preactivated
CD4 cells were either left unstimulated or restimulated with 2 g/ml
of anti-CD3 mAb for 1 h, followed by cross-linking with formaldehyde.
Formaldehyde-treated nuclear lysates were subjected to immunopre-
cipitation with antibodies specific for NFATc2. After treatment with
proteinase K to remove the protein and reversal of cross-links, the
amounts of selected DNA sequences were assessed by real time PCR.
The sequences of the primers and TaqMan probe for IL-21 promoter
were as follows: 5-GGCACATTTTGTGGACTCTATCC-3, 5-CCATTG-
CAGCCTGGAAATCT-3, and 5-(6-FAM)-AGCCAATGGAAAAGAAAA-
ACGAGTTACTCACACT-(TAMRA-6-FAM)-3. The sequences of the
primers and TaqMan probe for glyceraldehyde-3-phosphate dehydro-
genase were as follows: 5-TTCACCACCATGGAGAAGGC-3, 5-GGC-
ATGGACTGTGGTCATGA-3, and 5-(6-FAM)-TGCATCCTGCACCAC-
CAACTGCTTAG-(TAMRA-6-FAM)-3.
RESULTS
To investigate the regulation of IL-21 expression, we first
analyzed IL-21 mRNA levels in CD4 T cells. CD4 spleno-
cytes isolated from C57BL/6 mice were activated with anti-CD3
and anti-CD28 mAbs for 2 days, washed, and then cultured in
the presence of IL-2 for 1 day. These preactivated CD4 cells
were then either left unstimulated or restimulated with vari-
ous stimuli. IL-21 mRNA was increased 10-fold by anti-CD3
but not by anti-CD28 (Fig. 1A). Co-stimulation with both anti-
CD3 and anti-CD28 showed similar effects to those seen with
anti-CD3 alone (Fig. 1A). The induction of IL-21 mRNA was
primarily at the level of transcription because the transcription
inhibitor, actinomycin D, markedly diminished the inducibility
(Fig. 1A). This induction did not require de novo protein syn-
thesis, because the protein synthesis inhibitor, cycloheximide,
did not diminish and in fact increased IL-21 mRNA levels in
response to anti-CD3  anti-CD28 (Fig. 1A). Cycloheximide is
a protein synthesis inhibitor that superinduces the expression
of many genes by preventing the degradation of otherwise
labile mRNAs (15). Interestingly, IL-21 mRNA levels were
increased by ionomycin alone, whereas phorbol 12-myristate
13-acetate had little effect by itself and did not augment the
effect of ionomycin (Fig. 1A). This is in marked contrast to the
regulation of the IL-2 gene in which both phorbol 12-myristate
13-acetate and ionomycin are required for its expression
(16)(Fig. 1B). Consistent with the importance of a calcium
signal, rapamycin had no effect, but cyclosporin A and FK506
markedly inhibited induction of IL-21 mRNA in response to
ionomycin or anti-CD3anti-CD28 (Fig. 1A); this indicates a
role for the calcineurin/NFAT signaling pathway in IL-21
mRNA transcription.
To identify the regions of the IL-21 gene that mediate its
induction, we performed DNase I hypersensitivity assays with
preactivated CD4 T cells that were either unstimulated or
restimulated for 1 h with anti-CD3  anti-CD28. Nuclei were
then isolated and subjected to DNase I hypersensitivity assays.
DNA was extracted, digested with NsiI, which cleaves the
6.5-kb 5 and 7.1-kb 3 to the transcription start site, and
Southern blotted with the indicated probe. Two principal hy-
persensitive sites, HS1 (upstream of the previously reported
5-end of the IL-21 cDNA) and HS2 (in intron 2), were identi-
fied (Fig. 2). Both HS1 and HS2 were detected in the unstimu-
lated cells, and the intensities of these sites were modestly
increased in restimulated cells. The nucleotide sequences of
both the HS1 (Fig. 3A) and HS2 (Fig. 3B) regions are well
conserved in humans and mice, consistent with the presence of
important regulatory regions in these areas.
The transcriptional start site in the IL-21 gene was identi-
fied using 5-RACE and mRNA from activated CD4 T cells
(data not shown). Using an IL-21-specific primer (see “Materi-
als and Methods”), we identified a single product containing 69
bases of 5-untranslated mRNA; the 5-nucleotide was assigned
position 1 as indicated in Fig. 3A. The full-length mRNA is
thus 16 nucleotides longer than an mRNA previously reported
(NCBI accession number NM_021782). These data confirm that
there is not a cryptic upstream exon and that HS1 is located in
the proximal 5-regulatory region.
To test whether HS1 and HS2 correspond to TCR response
elements, each HS region was separately subcloned into a
luciferase reporter construct. When the HS1 region was used,
potent inducibility was observed in response to ionomycin as
well as anti-CD3  anti-CD28 (Fig. 4A), and this inducibility
was abrogated when the transfected cells were treated with
cyclosporin A 30 min before stimulation (Fig. 4A). In contrast,
when the construct containing the HS2 region was cloned in
either orientation and either 5 or 3 to the IL-21 or SV40
promoters, only minimal TCR inducibility was found in trans-
fection experiments in normal mouse splenocytes (Fig. 4B).
Thus, HS1 appeared to be more important for IL-21 gene reg-
ulation, and we have focused on HS1 in this study.
Analysis of HS1 revealed several potential consensus se-
quences for factor binding, including three consensus NFAT
FIG. 4. Cyclosporin inhibits IL-21 promoter activity. A, normal
murine T lymphocytes were transfected with a WT HS1 region reporter
construct. Transfected cells were incubated with medium, anti-CD3 
anti-CD28 (CD3  CD28), CsA, or anti-CD3  anti-CD28  CsA.
Data are shown as the mean S.E. B, fragments spanning HS2 (1139
to 1683) were generated by PCR and cloned in both orientations 5
and 3 to the SV40 promoter in pGL3-promoter. These constructs were
transfected into normal murine T lymphocytes and evaluated for their
TCR responsiveness.
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binding sites that are conserved in humans and mice (Fig. 3A).
We investigated factor binding to 32P-labeled probes spanning
these sites using EMSAs and nuclear extracts from unstimu-
lated or anti-CD3-stimulated mouse T cells. When probes span-
ning the NFAT sites at either 203 or 76 (Fig. 5A) were
assayed, only very faint complexes were detected with extracts
from either unstimulated or stimulated cells (Fig. 5B). How-
ever, the probe spanning the site at 121 (Fig. 5A) generated a
complex with extracts from unstimulated cells (Fig. 5, B, lane 3
and C, lane 1), which was modestly increased when cells were
stimulated with anti-CD3 (Fig. 5, B, lane 4 and C, lane 2). An
antibody to NFATc2 (also known as NFAT1 and NFATp) su-
pershifted the complex to generate a slower mobility complex,
with this effect being more evident in activated cells (Fig. 5C,
lanes 3 and 4). In contrast, an antibody to NFATc1 (also known
as NFAT2 and NFATc) had no effect (lanes 5 and 6). The
mutation of the NFAT site eliminated the formation of com-
plexes from resting (lane 7) and stimulated (lane 8) cells.
As a control, we also investigated factor binding to a probe
spanning the distal NFAT binding sites in the IL-2 gene. When
the IL-2 NFAT probe was used, the formation of complexes was
weaker than with the IL-21 probe. Some binding activity was
detected in unstimulated cells (lane 9), which increased follow-
ing stimulation with anti-CD3 (lane 10). The complex formed
with the IL-2 NFAT probe was evaluated for the presence of
NFATc1 and NFATc2 using antibodies to each protein. An
antibody to NFATc2 supershifted the complex to generate a
slower mobility complex (lanes 11 and 12), whereas the anti-
NFATc1 antibody almost completely blocked the formation of
complexes (lanes 13 and 14). Thus, both NFATc2 and NFATc1
proteins can bind to the IL-2 NFAT probe. In contrast, the
IL-21 NFAT probe appeared to preferentially bind NFATc2.
The fact that much of the complex formed with the IL-21 probe
was not supershifted suggested that additional protein(s) con-
tribute to the binding activity seen in unstimulated cells.
We next sought to confirm NFATc2 binding to the IL-21
promoter in vivo using chromatin immunoprecipitation assays.
Despite in vitro binding activity in both resting and stimulated
cells, we found a marked increase in NFATc2 binding in vivo
after cellular stimulation with anti-CD3 (Fig. 5D). No binding
of NFATc2 was observed to a control exon region of glyceral-
dehyde-3-phosphate dehydrogenase gene, indicating the speci-
ficity of the binding to IL-21 promoter. Thus, NFATc2 binding
in vivo corresponded to the induction of Il21 gene expression.
To determine whether NFATc2 was uniquely essential for
IL-21 induction, we next evaluated the ability of anti-CD3 and
anti-CD28 to induce IL-21 mRNA expression in NFATc2-defi-
cient mice. Interestingly, IL-21 mRNA induction was not di-
minished in these mice (Fig. 6). This is analogous to the normal
induction of IL-2 mRNA and increased induction of IL-4 mRNA
in these animals as well (Fig. 6) (17). The normal induction
despite the absence of NFATc2 suggests the compensation by
and action of other NFAT family proteins in vivo, as has been
suggested for the IL-2 and IL-4 genes as well (17).
Despite the normal induction of IL-21 mRNA in NFATc2
knock-out mice, our data overall suggested that the NFAT
binding sites were critical. Specifically, the inhibition by cyclos-
porin A of the induction of IL-21 mRNA (Fig. 1) and promoter
activity (Fig. 4) by anti-CD3 and anti-CD28 was consistent
with a critical role for the NFAT sites in the HS1 region. To
FIG. 5. NFAT bind to the IL-21 pro-
moter in vitro and in vivo. A, sequence
of the 203, 121, 76 (spanning the
216/182, 136/101, 89/55, re-
spectively), and IL-2 NFAT probes. For
the 121 probes, both wild type (WT) and
mutant (mt) probes are shown. Mutated
nucleotides are shown in lowercase, and
hyphens indicate identity to the WT se-
quence. B, EMSA using the 203, 121,
and 76 probes in A and nuclear extracts
from untreated preactivated mouse T
lymphocytes or from cells treated with an-
ti-CD3 (CD3) (see “Material and Meth-
ods”), as indicated. C, EMSA using the
WT and mutant121 probes and the IL-2
NFAT probe in A and nuclear extracts
from untreated mouse T lymphocytes
(lanes 1, 3, 5, 7, 9, 11, and 13) or from
anti-CD3-treated cells (lanes 2, 4, 6, 8, 10,
12, and 14) in the presence of antibodies
to NFATc2 (lanes 3, 4, 11, and 12) or
NFATc1 (lanes 5, 6, 13, and 14), as indi-
cated. D, chromatin immunoprecipitation
assays reveal inducible NFAT binding to
the IL-21 promoter in vivo. Murine T lym-
phocytes were cultured in the absence or
presence of anti-CD3 for 1 h, and then
chromatin immunoprecipitation assays
were performed with preimmune serum
or anti-NFATc2. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used
as a negative control. Data are shown as
the mean  S.E.
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further define their role, we mutated each NFAT site individ-
ually and in combination and assayed the TCR responsiveness
of each mutant construct in normal mouse T lymphocytes.
Whereas the wild type construct showed 15-fold TCR induc-
ibility, selective mutation of the NFAT sites at 203 (mutant
m1) and 76 (mutant m3) markedly decreased TCR inducibil-
ity (Fig. 7), even though these sites individually show little
binding by EMSA (Fig. 5B). Selective mutation of the site at
121 most potently bound factors in vitro (mutant m2) or
double mutation of any two of the sites (mutants m4, m5, and
m6) even more potently decreased TCR inducibility, whereas
simultaneous mutation of all three NFAT sites (mutant m7)
abrogated TCR inducibility (Fig. 7). These results suggest
that all of the NFAT sites are required for maximal TCR
inducibility and are consistent with at least some factor
binding to all three sites in vivo; this binding may be coop-
erative. By itself, the 121 NFAT site nevertheless appears
to be the most important.
DISCUSSION
IL-21 is a type I cytokine that is made by activated T cells
and exerts actions on B cells, T cells, and NK cells. Its receptor
is most like the IL-2 receptor  chain and the gene encoding
IL-21 is adjacent to the Il2 gene. Similar induction patterns
might have suggested similar regulation for these two genes,
and our mutagenesis data indicate that the Il21 gene, analo-
gous to the Il2 gene, is dependent on NFAT binding sites.
NFAT proteins are expressed in most immune system cells
and play a pivotal role in the transcription of cytokine genes
and other genes critical for the immune response (18–20).
NFAT was first identified in T cells as a rapidly inducible
nuclear factor binding to the distal antigen receptor response
element of the human IL-2 promoter (21). Subsequently,
studies from several laboratories indicated that the promot-
er/enhancer regions of different activation genes possessed
binding sites for NFAT family proteins, including the cyto-
kines IL-2 (22–28), IL-4 (29), IL-5 (30), IL-13 (31), interfer-
on- (32), tumor necrosis factor- (33, 34), and granulocyte
monocyte colony-stimulating factor (35, 36), as well as the
cell surface receptors IL-2 receptor- chain (13), CD40L (37,
38), and CTLA-4 (39). Based on comparison of these se-
quences, the NFAT binding site consensus is (A/T)GGAAA(A/
N)(A/T/C)N (19).
The activity of NFAT proteins is tightly regulated by the
calcium/calmodulin-dependent phosphatase calcineurin, a pri-
mary target for inhibition by cyclosporin A and FK506 (19).
Calcineurin controls the translocation of NFAT proteins from
the cytoplasm to the nucleus of activated cells by interacting
with an N-terminal regulatory domain conserved in the NFAT
family.
In this study, we have described a TCR response element in
the 5-regulatory region of the Il21 gene. Several results sup-
port the hypothesis that NFAT is required for TCR-mediated
transactivation of the Il21 gene. First, the critical IL-21 pro-
moter region contains three NFAT binding sites, the nucleotide
FIG. 6.Normal induction of IL-21 and IL-2 mRNA in NFATc2/
mice. Preactivated murine CD4 lymphocytes from WT or NFATc2/
mice were stimulated with immobilized anti-CD3 (CD3  CD28)
antibody for 4 h, and levels of IL-21, IL-2, and IL-4 mRNA were
analyzed by real time PCR. Where indicated, CsA was added 30 min
before TCR cross-linking. For each sample, the bar represents the ratio
of IL-21, IL-2, or IL-4 mRNA to that of 18 S ribosomal mRNA. Data are
shown as the mean  S.E.
FIG. 7. The NFAT binding sites in
the promoter are essential for TCR-
induced IL-21 gene expression. Muta-
tions in the NFAT sites were made in the
context of the WT 1605/75 murine IL-
21-luciferase reporter construct, as indi-
cated. Constructs were transfected into
normal mouse splenic T cells, followed by
no stimulation or stimulation with anti-
CD3  anti-CD28 (CD3  CD28) for
14 h. Data are shown as the mean  S.E.
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sequence of the IL-21 promoter is evolutionarily conserved, and
a chromatin immunoprecipitation assay showed the in vivo
binding activity of NFATc2 to this region. Second, site-specific
mutagenesis of these NFAT sites significantly diminished
IL-21 promoter activity. Third, CsA, an inhibitor of calcineurin
that potently inhibits nuclear translocation ofNFATandNFAT-
dependent transcription (19, 40, 41), markedly decreased TCR-
mediated transactivation of IL-21 promoter and IL-21 gene
expression, implying that calcineurin regulates IL-21 gene
transcription. Transient transfection experiments using lucif-
erase reporter constructs showed that CsA could almost com-
pletely block anti-CD3  anti-CD28-mediated IL-21 promoter
activity, and this specific role of the NFAT binding sites was
confirmed using a construct in which all three NFAT sites were
mutated. The fact that NFATc2/mice had normal IL-21 gene
induction is consistent with the potential utilization of more
than one NFAT-binding protein in vivo.
Recently, Mehta et al. (42) reported that NFATc2 and T-bet
contribute to Th2-specific regulation of IL-21 expression. They
studied IL-21 expression in EL4 and D10 cells, and like us, they
found that three NFAT binding sites were important for TCR-
stimulated IL-21 promoter activity. We demonstrate in pri-
mary T cells the importance of this region and moreover that
the chromatin structure in the promoter region has an open
conformation. However, our data differ from those of Mehta et
al. (42) in that we find that IL-21 expression remains strong in
NFATc2 knock-out T cells. The basis for this dissimilarity is
unclear.
Despite the evidence in support of NFAT recruitment to the
Il2 and Il4 genes (19, 43) as well as the Il21 gene, the tran-
scription of the Il21 gene in preactivated T cells is strikingly
different from the genes encoding IL-2 and IL-4 in that it can be
mediated by calcium ionophore alone without requiring protein
synthesis or protein kinase C activation. Thus, our studies
demonstrate that IL-21 induction by antigen in primary T cells
is primarily dependent on a calcium signal and contrasts in this
regard to these other activation-dependent cytokines that re-
quire both calcium and protein kinase C signals (e.g. IL-2 and
IL-4) or to another activation-dependent protein whose expres-
sion only requires a protein kinase C signal (e.g. IL-2 receptor
 chain). The lack of a requirement for a protein kinase C
signal for IL-21 expression suggests that AP1 family proteins
are not important or are much less important for Il21 gene
induction than for induction of the Il2 gene. It is interesting to
speculate that the constitutive DNA binding activity seen even
with untreated preactivated cell extracts (Fig. 5B) could con-
tribute to the ability of ionomycin alone to activate the gene. In
other words, the constitutive DNA binding activity in vitromay
correspond to a factor that can cooperate with NFAT proteins
in vivo, suggesting that the Il21 gene is poised to receive and
respond to a calcium signal as a major component of its regu-
lation. The characterization of such a factor is an interesting
area for future investigation. In summary, we have demon-
strated properties of regulation of the Il21 gene and have
characterized a critical region containing NFAT binding sites
that corresponds to a hypersensitive site, clarifying the molec-
ular basis for the rapid induction of Il21 gene expression in T
cells.
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